This table refers to the formula (1) compounds as mPGES-1 inhibitors and the pharmaceutically acceptable salts of these compounds. These compounds inhibit prostaglandin E1 microcellular hybridase (mPGES-1) and thus contribute to the treatment of pain and / or inflammation of various diseases or symptoms, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain, and neurodegenerative diseases. 1. Characteristic 1: a formula compound (1) or a salt from which drug acceptance can be obtained, wherein Y is O, NH or n758080；Z1 and Z3,It can be the same or different, and can be selected independentlyG1 is selected from N and Cr * m；If there is at least one Z1,Z3 and G1 sea n； Q1,Q2,Q3 and q830808；a. May be the same or different, independent of N, CH and cr83088；But there is a conditionQ³ and Q⁴ are not N simultaneously； W is selected from substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₁₋₈alkoxy, substituted or unsubstituted C₁₋₈ haloalkyl, substituted or unsubstituted C₁₋₈ hydroxyalkyl, substituted or unsubstituted C₃₋₁₂ cycloalkyl substituted and substituted or unsubstituted tetrahydrofuryl or tetrahydrofuranyl； R¹ is selected from substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₁₋₈alkoxy, substituted or unsubstituted C₁₋₈ haloalkyl, substituted or unsubstituted C₁₋₈ hydroxyalkyl, substituted or unsubstituted C₃₋₁₂ cycloalkyl replaced,C₆₋₁₄ substituted or unsubstituted aryl, 3-15 substituted or unsubstituted heterocyclyl and substituted or unsubstituted 5-14 membered heteroaryl； each occurrence of R² and R³,which may be the same or different, is independently selected from hydrogen, halogen, nitro, cyano, hydroxyl, substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₁₋₈ alkoxy, substituted or unsubstituted C₁₋₈ haloalkyl, C₁ hydroxyalkyl ₋₈ substituted or unsubstituted, C₃₋₁₂ substituted or unsubstituted cycloalkyl and substituted or unsubstituted C₃₋₈ cycloalkyl； at each occurrence, R⁴ i
